Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H, Thursz M
Hepatology Section, Division of Medicine A, Imperial College School of Medicine at St Mary's Hospital, Praed St, London W2 1NY, UK.
Gut. 2003 Aug;52(8):1206-10. doi: 10.1136/gut.52.8.1206.
The rate of progression to cirrhosis varies among individuals chronically infected with the hepatitis C virus (HCV). Coagulation pathway activation in models of hepatic fibrosis suggests variation in coagulation pathway components may influence the rate of fibrosis. We hypothesised that polymorphisms of the coagulation factors II and V affect the rate of progression to cirrhosis in HCV infected subjects.
We studied the relationship between rate of fibrosis (calculated by dividing the fibrosis stage by duration of infection) and genotypes of specific coagulation pathway genes in 352 White European patients infected with HCV. Genotyping was performed using reverse line blot hybridisation.
The rate of fibrosis was significantly higher in patients with the factor V Leiden genotype (Arg560Gln) (ANOVA, p=0.004). In disease association studies, a significant association was seen (Fisher's exact test, p=0.029; odds ratio 3.28 for fast progression to cirrhosis (expected to reach cirrhosis in less than 30 years) if heterozygous for factor V Leiden). No associations were seen between factor II genotype and fibrosis rate.
Possession of the factor V Leiden polymorphism significantly increases the risk of rapid disease progression in HCV, suggesting a role for the coagulation system in the pathogenesis of fibrotic liver disease.
丙型肝炎病毒(HCV)慢性感染个体发展为肝硬化的速率存在差异。肝纤维化模型中的凝血途径激活表明,凝血途径成分的差异可能影响纤维化速率。我们推测凝血因子II和V的多态性会影响HCV感染患者发展为肝硬化的速率。
我们研究了352名感染HCV的欧洲白人患者的纤维化速率(通过纤维化分期除以感染持续时间计算)与特定凝血途径基因的基因型之间的关系。使用反向线印迹杂交进行基因分型。
携带因子V莱顿基因型(Arg560Gln)的患者纤维化速率显著更高(方差分析,p = 0.004)。在疾病关联研究中,观察到显著关联(Fisher精确检验,p = 0.029;如果为因子V莱顿杂合子,快速进展为肝硬化(预计在不到30年达到肝硬化)的优势比为3.28)。未观察到因子II基因型与纤维化速率之间的关联。
携带因子V莱顿多态性显著增加了HCV患者疾病快速进展的风险,提示凝血系统在肝纤维化疾病发病机制中发挥作用。